Trial Profile
Multi-center, Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of Activated Recombinant Factor VII (NovoSeven) for Preventing Early Hematoma Growth in Acute Intracerebral Hemorrhage (ICH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Cerebral haemorrhage
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 15 Apr 2015 New trial record